For the Inventor, By the Inventor

Enter assignee name

Jersey City, NJ, United States of America

Scynexis, Inc.

USPTO Granted Patents = 19

% Expired Patents = 42.1

CIPO Patents = 2

EPO Patents = 15

Trademarks = 3

Forward Citations = 51

Loading Chart...

Loading Chart...

28 inventors (with patents filed for the assignee):

David Renwick Houck (8 out of 8 patents)

Michael Robert Peel (4 out of 8 patents)

Yi Zhang (3 out of 16 patents)

4. David A Angulo Gonzalez (3 out of 3 patents)

5. Keqiang Li (3 out of 5 patents)

6. Ahmed Mamai (3 out of 5 patents)

7. Andrew Scribner (2 out of 12 patents)

8. Weiming Fan (2 out of 9 patents)

9. Hans Georg Fliri (2 out of 2 patents)

10. James M Balkovec (2 out of 47 patents)

11. Frances A Bouffard (2 out of 18 patents)

12. Phieng Siliphaivanh (1 out of 34 patents)

13. Rebecca A Chmielowski (1 out of 2 patents)

14. Hao Liu (1 out of 3 patents)

15. Dongfang Meng (1 out of 23 patents)

19 patents: Sort by Forward Citations

1. 12594266 - Triterpenoid antifungals for the treatment or prevention ofspp. pneumonia (2026-04-07),

2. 11534433 - Antifungal agents with enhanced activity in acidic pH (2022-12-27),

3. 11110102 - Antifungal agents used in combination (2021-09-07),

4. 10927142 - Salts and polymorphs of SCY-078 (2021-02-23),

5. 10370406 - Salts and polymorphs of SCY-078 (2019-08-06),

6. 10174074 - Salts and polymorphs of SCY-078 (2019-01-08),

7. 9090671 - Macrocyclic peptides (2015-07-28),

8. 8674087 - Processes for isolation and purification of enfumafungin (2014-03-18),

9. 8551952 - Methods for the treatment and prevention of ocular disorders (2013-10-08),

10. 8536114 - Macrocycles (2013-09-17),

11. 8329658 - Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection (2012-12-11),

12. 8222255 - Antifungal agents (2012-07-17),

13. 8188052 - Method for the treatment and prevention of ocular disorders (2012-05-29),

14. 7863465 - Antifungal agents (2011-01-04),

15. 7754685 - Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection (2010-07-13),

Scynexis, Inc. is a biotechnology company that develops and delivers innovative therapies for difficult-to-treat and often life-threatening infections. The company focuses on developing novel anti-infectives to address unmet medical needs. Scynexis utilizes its proprietary drug discovery platform to develop a pipeline of potential drug candidates. With a commitment to improving patients' lives, Scynexis aims to provide effective treatments for serious infections.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

19 Patents

#12 in Jersey City, NJ

#646 in New Jersey

#17,104 in US

#32,571 in the World

Jersey City, NJ, United States of America

Scynexis, Inc.

Forward Citations = 51

28 inventors:

David Renwick Houck (8 out of 8 patents)

Michael Robert Peel (4 out of 8 patents)

Yi Zhang (3 out of 16 patents)

4. David A Angulo Gonzalez (3 out of 3 patents)

5. Keqiang Li (3 out of 5 patents)

Please report any incorrect information to [email protected]

Loading…